Alpha Tau to Present Complete Top-Line Data for Alpha DaRT Head & Neck Cancer Combination Therapy at AHNS Conference
Summary
Alpha Tau Medical will present complete top-line data from its Alpha DaRT combination therapy trial for head and neck cancer at a major international conference, signaling significant progress in its clinical development.
Key Events
-
Podium Presentation Acceptance
An abstract showcasing complete top-line data from a clinical study of Alpha DaRT in combination with pembrolizumab for head and neck cancer has been accepted for a podium presentation at the AHNS 12th International Conference on Head and Neck Cancer in July 2026.
-
Combination Therapy for HNSCC
The study evaluates Alpha DaRT in combination with pembrolizumab for elderly patients with locally advanced and metastatic head and neck squamous cell carcinoma (HNSCC), addressing a significant unmet medical need.
-
Strategic Milestone
The company views this as a strategic milestone, advancing its head and neck cancer program and combination therapy strategy, building on strong monotherapy data.
Analysis
Alpha Tau Medical announced that complete top-line data from its clinical study evaluating Alpha DaRT in combination with pembrolizumab for elderly patients with locally advanced and metastatic head and neck squamous cell carcinoma (HNSCC) has been accepted for a podium presentation at the prestigious AHNS 12th International Conference. This selection signifies the scientific merit and clinical significance of the findings, building on previous interim data. The combination therapy targets a high unmet medical need in a vulnerable patient population, representing a strategic milestone for the company's pipeline and its combination therapy strategy.
At the time of this filing, DRTS was trading at $7.89 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $662.7M. The 52-week trading range was $2.55 to $9.07. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.